Keywords: Biomarkers, Molecular Imaging, Melanoma, BRAF
Motivation: We use 1H/31P MRS to monitor the metabolic effects of dabrafenib therapy in four human melanoma models, an FDA-approved treatment for late-stage melanoma.
Goal(s): Differences in relative levels of metabolites and bioenergetics between four melanoma models may produce differential therapeutic responses to BRAF inhibitors.
Approach: Intratumor variations of lactate, alanine, and bioenergetics (β-NTP/Pi) measured by in-vivo and in-vitro 1H/31P MRS have the potential to become early and sensitive biomarkers of dabrafenib inhibition therapy in melanoma.
Results: Changes in lactate, alanine, and bioenergetics response to targeted dabrafenib inhibitor therapy occur rapidly and are connected to the following tumor response.
Impact: Dabrafenib blocks cell division by inhibiting the hyperactive BRAF protein. Differences in the predominance of metabolites (Lactate and Alanine) and bioenergetics may explain dabrafenib therapeutic responses in DB-1/WM983B (Sensitive mutant type), WM983BR (Resistant mutant type), and WM3918 (Wild type).
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords